CardiovascularResearch Phase

Urocortin 3

Intravenous

Overview

Urocortin 3, also known as stresscopin, is a 38-amino acid peptide with high selectivity for CRF receptor 2. It produces vasodilation and increases cardiac contractility while exhibiting cardioprotective effects in models of cardiac stress and injury.

Mechanism of Action

The selective CRF2 receptor activation avoids hypothalamic-pituitary-adrenal axis stimulation, potentially offering a favorable profile for cardiovascular therapeutics..

Research Summary & Key Findings

Animal studies have shown that urocortin 3 improves hemodynamics and reduces infarct size in models of myocardial ischemia and heart failure. No clinical trial data in human cardiovascular disease have been published, and the peptide remains in preclinical investigation.

Clinical Status

Research Phase

Urocortin 3 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Urocortin 3 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Urocortin 3.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.